Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
HHS Awards $295 Million in Funding to Expand Primary Care Services
More than 1,000 health centers in every US state and territory will receive Affordable Care Act funds to expand their primary care services, according to an announcement from Health and Human Services' Secretary Sylvia M. Burwell.
Making Treatment Decisions When There Is an Abundance of Options
Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis, the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
The Power of Treating Patients as Partners in MS Clinical Research
As a medium, the Internet neither helps nor harms in multiple sclerosis care - what matters is how clinicians and patients engage in that medium, according to Paul Wicks, PhD, vice president of innovation at PatientsLikeMe.
Improving Patient-Clinician Communication and Treatment Adherence
Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Engaging Patients in Their Own Treatment Decisions
Patients with multiple sclerosis want to be actively engaged in their treatment decisions, which will help their long-term health and medication adherence, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Heterogeneity of MS Makes New Disease Biomarker Discovery Difficult
The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
PML is Treatable in MS, but Long-Term Function Can Remain Affected
Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, Ralf Gold, Ruhr University Bochum in Germany, said at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Using Advanced Imaging Techniques to Better Understand MS Progression
Advanced imaging techniques are becoming necessary to further understanding of the progression of multiple sclerosis, according to presenters at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, from September 10-13.
Collaborative Decision Making Tops Efficacy for MS Patients
When choosing treatment for a patient, whether he or she has a clinically isolated syndrome or clinically definite multiple sclerosis, providers need to establish a collaborative relationship, according to speakers at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Premiums for ACA Insurance Plans Will Decline Slightly in 2015
In the largest cities in 15 states plus the District of Columbia the average insurance premiums for the second-lowest-cost silver plan will decline by 0.8% in 2015, according to an analysis from the Kaiser Family Foundation.
ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis
The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).